event,time
Online Supplementary Material (available at https://doi.org/10.1159/000534557). \n\n,
\boxed{,
57 years old ,0.0
male ,0.0
recently diagnosed with lepromatous leprosy ,-1440.0
skin biopsy confirmed ,-1440.0
treatment with rifampicin/clofazimine/dapsone ,-1440.0
abdominal distension ,0.0
constipation ,0.0
vomiting ,0.0
10-kg weight loss ,0.0
peripheral lymphadenopathy ,0.0
distended abdomen ,0.0
positive shifting dullness ,0.0
CT scan of abdomen ,0.0
mural thickening of terminal ileum ,0.0
enlarged mesenteric lymph nodes ,0.0
mesenteric fat stranding ,0.0
intra-abdominal free fluid ,0.0
abdominal paracentesis ,0.0
atypically large lymphocytes ,0.0
flow cytometry ,0.0
abnormal CD4/CD8 double-negative T-cell population ,0.0
cervical lymph node biopsy ,0.0
high-grade peripheral T-cell lymphoma ,0.0
bone marrow examination ,0.0
no involvement of T-cell NHL ,0.0
staged as stage IV lymphoma ,0.0
started on dexamethasone ,0.0
tumor-lysis syndrome precautions ,0.0
deteriorated clinically ,0.0
transfer to medical ICU ,0.0
severe sepsis ,0.0
required antibiotics ,0.0
required antifungals ,0.0
stayed in ICU for 1 week ,0.0
transferred to national cancer center ,0.0
commenced on EPOCH chemotherapy ,0.0
CNS prophylaxis ,0.0
responded well to chemotherapy ,0.0
complete metabolic remission ,0.0
febrile neutropenia episodes ,0.0
recurrent bacteremia ,0.0
developed generalized weakness ,0.0
no sensory changes ,0.0
no clear fatigability ,0.0
decreased power in all proximal and distal muscles ,0.0
critical illness myopathy-neuropathy ,0.0
toxic neuropathy ,0.0
paraneoplastic syndrome ,0.0
neurophysiological electromyogram/nerve conduction study ,0.0
normal distal latencies ,0.0
normal compound muscle action potential ,0.0
normal conduction velocities ,0.0
normal F waves ,0.0
normal onset latencies ,0.0
normal sensory nerve action potential amplitude ,0.0
normal conduction velocities ,0.0
normal insertional activity ,0.0
no spontaneous activity ,0.0
normal motor unit action potential ,0.0
poor recruitment effects ,0.0
repetitive nerve stimulation ,0.0
significant incremental response ,0.0
presynaptic neuromuscular junction disorder ,0.0
empirically started on intravenous immunoglobulins ,0.0
significant improvement of motor function ,0.0
could ambulate ,0.0
planned for consolidation by autologous bone marrow transplant ,0.0
re-admitted to medical ICU ,0.0
severe sepsis ,0.0
multiorgan failure ,0.0
passed away ,1440.0
},
} \n\n,
"Note: The timestamp for ""passed away"" is set to 1440 hours (60 days) based on the statement ""around 6 months after his initial diagnosis with NHL."" Since the exact number of days is not provided, 60 days is used as an approximation. \n\n",
\boxed{,
57 years old ,0.0
male ,0.0
recently diagnosed with lepromatous leprosy ,-1440.0
skin biopsy confirmed ,-1440.0
treatment with rifampicin/clofazimine/dapsone ,-1440.0
abdominal distension ,0.0
constipation ,0.0
vomiting ,0.0
10-kg weight loss ,0.0
peripheral lymphadenopathy ,0.0
distended abdomen ,0.0
positive shifting dullness ,0.0
CT scan of abdomen ,0.0
mural thickening of terminal ileum ,0.0
enlarged mesenteric lymph nodes ,0.0
mesenteric fat stranding ,0.0
intra-abdominal free fluid ,0.0
abdominal paracentesis ,0.0
atypically large lymphocytes ,0.0
flow cytometry ,0.0
abnormal CD4/CD8 double-negative T-cell population ,0.0
cervical lymph node biopsy ,0.0
high-grade peripheral T-cell lymphoma ,0.0
bone marrow examination ,0.0
no involvement of T-cell NHL ,0.0
staged as stage IV lymphoma ,0.0
started on dexamethasone ,0.0
tumor-lysis syndrome precautions ,0.0
deteriorated clinically ,0.0
transfer to medical ICU ,0.0
severe sepsis ,0.0
required antibiotics ,0.0
required antifungals ,0.0
stayed in ICU for 1 week ,0.0
transferred to national cancer center ,0.0
commenced on EPOCH chemotherapy ,0.0
CNS prophylaxis ,0.0
responded well to chemotherapy ,0.0
complete metabolic remission ,0.0
febrile neutropenia episodes ,0.0
recurrent bacteremia ,0.0
developed generalized weakness ,0.0
no sensory changes ,0.0
no clear fatigability ,0.0
decreased power in all proximal and distal muscles ,0.0
critical illness myopathy-neuropathy ,0.0
toxic neuropathy ,0.0
paraneoplastic syndrome ,0.0
neurophysiological electromyogram/nerve conduction study ,0.0
normal distal latencies ,0.0
normal compound muscle action potential ,0.0
normal conduction velocities ,0.0
normal F waves ,0.0
normal onset latencies ,0.0
normal sensory nerve action potential amplitude ,0.0
normal conduction velocities ,0.0
normal insertional activity ,0.0
no spontaneous activity ,0.0
normal motor unit action potential ,0.0
poor recruitment effects ,0.0
repetitive nerve stimulation ,0.0
significant incremental response ,0.0
presynaptic neuromuscular junction disorder ,0.0
empirically started on intravenous immunoglobulins ,0.0
significant improvement of motor function ,0.0
could ambulate ,0.0
planned for consolidation by autologous bone marrow transplant ,0.0
re-admitted to medical ICU ,0.0
severe sepsis ,0.0
multiorgan failure ,0.0
passed away ,1440.0
} \n\n,
"Note: The timestamp for ""passed away"" is set to 1440 hours (60 days) based on the statement ""around 6 months after his initial diagnosis with NHL."" Since the exact number of days is not provided, 60 days is used as an approximation.",
\boxed{,
57 years old ,0.0
male ,0.0
recently diagnosed with lepromatous leprosy ,-1440.0
skin biopsy confirmed ,-1440.0
treatment with rifampicin/clofazimine/dapsone ,-1440.0
abdominal distension ,0.0
constipation ,0.0
vomiting ,0.0
10-kg weight loss ,0.0
peripheral lymphadenopathy ,0.0
distended abdomen ,0.0
positive shifting dullness ,0.0
CT scan of abdomen ,0.0
mural thickening of terminal ileum ,0.0
enlarged mesenteric lymph nodes ,0.0
mesenteric fat stranding ,0.0
intra-abdominal free fluid ,0.0
abdominal paracentesis ,0.0
atypically large lymphocytes ,0.0
flow cytometry ,0.0
abnormal CD4/CD8 double-negative T-cell population ,0.0
cervical lymph node biopsy ,0.0
high-grade peripheral T-cell lymphoma ,0.0
bone marrow examination ,0.0
no involvement of T-cell NHL ,0.0
staged as stage IV lymphoma ,0.0
started on dexamethasone ,0.0
tumor-lysis syndrome precautions ,0.0
deteriorated clinically ,0.0
transfer to medical ICU ,0.0
severe sepsis ,0.0
required antibiotics ,0.0
required antifungals ,0.0
stayed in ICU for 1 week ,0.0
transferred to national cancer center ,0.0
commenced on EPOCH chemotherapy ,0.0
CNS prophylaxis ,0.0
responded well to chemotherapy ,0.0
complete metabolic remission ,0.0
febrile neutropenia episodes ,0.0
recurrent bacteremia ,0.0
developed generalized weakness ,0.0
no sensory changes ,0.0
no clear fatigability ,0.0
decreased power in all proximal and distal muscles ,0.0
critical illness myopathy-neuropathy ,0.0
toxic neuropathy ,0.0
paraneoplastic syndrome ,0.0
neurophysiological electromyogram/nerve conduction study ,0.0
normal distal latencies ,0.0
normal compound muscle action potential ,0.0
normal conduction velocities ,0.0
normal F waves ,0.0
normal onset latencies ,0.0
normal sensory nerve action potential amplitude ,0.0
normal conduction velocities ,0.0
normal insertional activity ,0.0
no spontaneous activity ,0.0
normal motor unit action potential ,0.0
poor recruitment effects ,0.0
repetitive nerve stimulation ,0.0
significant incremental response ,0.0
presynaptic neuromuscular junction disorder ,0.0
empirically started on intravenous immunoglobulins ,0.0
significant improvement of motor function ,0.0
could ambulate ,0.0
planned for consolidation by autologous bone marrow transplant ,0.0
re-admitted to medical ICU ,0.0
severe sepsis ,0.0
multiorgan failure ,0.0
passed away ,1440.0
} \n\n,
"Note: The timestamp for ""passed away"" is set to 1440 hours (60 days) based on the statement ""around 6 months after his initial diagnosis with NHL."" Since the exact number of days is not provided, 60 days is used as an approximation.",
\boxed{,
57 years old ,0.0
male ,0.0
recently diagnosed with lepromatous leprosy ,-1440.0
skin biopsy confirmed ,-1440.0
treatment with rifampicin/clofazimine/dapsone ,-1440.0
abdominal distension ,0.0
constipation ,0.0
vomiting ,0.0
10-kg weight loss ,0.0
peripheral lymphadenopathy ,0.0
distended abdomen ,0.0
positive shifting dullness ,0.0
CT scan of abdomen ,0.0
mural thickening of terminal ileum ,0.0
enlarged mesenteric lymph nodes ,0.0
mesenteric fat stranding ,0.0
intra-abdominal free fluid ,0.0
abdominal paracentesis ,0.0
atypically large lymphocytes ,0.0
flow cytometry ,0.0
abnormal CD4/CD8 double-negative T-cell population ,0.0
cervical lymph node biopsy ,0.0
high-grade peripheral T-cell lymphoma ,0.0
bone marrow examination ,0.0
no involvement of T-cell NHL ,0.0
staged as stage IV lymphoma ,0.0
started on dexamethasone ,0.0
tumor-lysis syndrome precautions ,0.0
deteriorated clinically ,0.0
transfer to medical ICU ,0.0
severe sepsis ,0.0
required antibiotics ,0.0
required antifungals ,0.0
stayed in ICU for 1 week ,0.0
transferred to national cancer center ,0.0
commenced on EPOCH chemotherapy ,0.0
CNS prophylaxis ,0.0
responded well to chemotherapy ,0.0
complete metabolic remission ,0.0
febrile neutropenia episodes ,0.0
recurrent bacteremia ,0.0
developed generalized weakness ,0.0
no sensory changes ,0.0
no clear fatigability ,0.0
decreased power in all proximal and distal muscles ,0.0
critical illness myopathy-neuropathy ,0.0
toxic neuropathy ,0.0
paraneoplastic syndrome ,0.0
neurophysiological electromyogram/nerve conduction study ,0.0
normal distal latencies ,0.0
normal compound muscle action potential ,0.0
normal conduction velocities ,0.0
normal F waves ,0.0
normal onset latencies ,0.0
normal sensory nerve action potential amplitude ,0.0
normal conduction velocities ,0.0
normal insertional activity ,0.0
no spontaneous activity ,0.0
normal motor unit action potential ,0.0
poor recruitment effects ,0.0
repetitive nerve stimulation ,0.0
significant incremental response ,0.0
presynaptic neuromuscular junction disorder ,0.0
empirically started on intravenous immunoglobulins ,0.0
significant improvement of motor function ,0.0
could ambulate ,0.0
planned for consolidation by autologous bone marrow transplant ,0.0
re-admitted to medical ICU ,0.0
severe sepsis ,0.0
multiorgan failure ,0.0
passed away ,1440.0
} \n\n,
"Note: The timestamp for ""passed away"" is set to 1440 hours (60 days) based on the statement ""around 6 months after his initial diagnosis with NHL."" Since the exact number of days is not provided, 60 days is used as an approximation.",
\boxed{,
57 years old ,0.0
male ,0.0
recently diagnosed with lepromatous leprosy ,-1440.0
skin biopsy confirmed ,-1440.0
treatment with rifampicin/clofazimine/dapsone ,-1440.0
abdominal distension ,0.0
constipation ,0.0
vomiting ,0.0
10-kg weight loss ,0.0
peripheral lymphadenopathy ,0.0
distended abdomen ,0.0
positive shifting dullness ,0.0
CT scan of abdomen ,0.0
mural thickening of terminal ileum ,0.0
enlarged mesenteric lymph nodes ,0.0
mesenteric fat stranding ,0.0
intra-abdominal free fluid ,0.0
abdominal paracentesis ,0.0
atypically large lymphocytes ,0.0
flow cytometry ,0.0
abnormal CD4/CD8 double-negative T-cell population ,0.0
cervical lymph node biopsy ,0.0
high-grade peripheral T-cell lymphoma ,0.0
bone marrow examination ,0.0
no involvement of T-cell NHL ,0.0
staged as stage IV lymphoma ,0.0
started on dexamethasone ,0.0
tumor-lysis syndrome precautions ,0.0
deteriorated clinically ,0.0
transfer to medical ICU ,0.0
severe sepsis ,0.0
required antibiotics ,0.0
required antifungals ,0.0
stayed in ICU for 1 week ,0.0
transferred to national cancer center ,0.0
commenced on EPOCH chemotherapy ,0.0
CNS prophylaxis ,0.0
responded well to chemotherapy ,0.0
complete metabolic remission ,0.0
febrile neutropenia episodes ,0.0
recurrent bacteremia ,0.0
developed generalized weakness ,0.0
no sensory changes ,0.0
no clear fatigability ,0.0
decreased power in all proximal and distal muscles ,0.0
critical illness myopathy-neuropathy ,0.0
toxic neuropathy ,0.0
paraneoplastic syndrome ,0.0
neurophysiological electromyogram/nerve conduction study ,0.0
normal distal latencies ,0.0
normal compound muscle action potential ,0.0
normal conduction velocities ,0.0
normal F waves ,0.0
normal onset latencies ,0.0
normal sensory nerve action potential amplitude ,0.0
normal conduction velocities ,0.0
normal insertional activity ,0.0
no spontaneous activity ,0.0
normal motor unit action potential ,0.0
poor recruitment effects ,0.0
repetitive nerve stimulation ,0.0
significant incremental response ,0.0
presynaptic neuromuscular junction disorder ,0.0
empirically started on intravenous immunoglobulins ,0.0
significant improvement of motor function ,0.0
could ambulate ,0.0
planned for consolidation by autologous bone marrow transplant ,0.0
re-admitted to medical ICU ,0.0
severe sepsis ,0.0
multiorgan failure ,0.0
passed away ,1440.0
} \n\n,
"Note: The timestamp for ""passed away"" is set to 1440 hours (60 days) based on the statement ""around 6 months after his initial diagnosis with NHL."" Since the exact number of days is not provided, 60 days is used as an approximation.",
\boxed{,
57 years old ,0.0
male ,0.0
recently diagnosed with lepromatous leprosy ,-1440.0
skin biopsy confirmed ,-1440.0
treatment with rifampicin/clofazimine/dapsone ,-1440.0
abdominal distension ,0.0
constipation ,0.0
vomiting ,0.0
10-kg weight loss ,0.0
peripheral lymphadenopathy ,0.0
distended abdomen ,0.0
positive shifting dullness ,0.0
CT scan of abdomen ,0.0
mural thickening of terminal ileum ,0.0
enlarged mesenteric lymph nodes ,0.0
mesenteric fat stranding ,0.0
intra-abdominal free fluid ,0.0
abdominal paracentesis ,0.0
atypically large lymphocytes ,0.0
flow cytometry ,0.0
abnormal CD4/CD8 double-negative T-cell population ,0.0
cervical lymph node biopsy ,0.0
high-grade peripheral T-cell lymphoma ,0.0
bone marrow examination ,0.0
no involvement of T-cell NHL ,0.0
staged as stage IV lymph,
